pharma-services
(6)
The Deck That Went Nowhere
A year of careful medical-communications work once died unused in the field. Kinetix Health Group is betting that pharma does not need another deck - it needs a system that keeps evidence moving.
The Investors Who Stay for the Whole Story
For more than three decades, Baird Capital has backed founder-led B2B technology and services companies from an early venture check to a late-stage buyout - one global team, one employee-owned firm, and a preference for the sectors most people scroll past.
The Doctor Who Traded the Exam Room for the Cap Table
A physician-turned-financier is buying up the unglamorous engine room of American healthcare - the home aides, clinical trial sites and hospice teams that most funds overlook.
The Firm That Bets on the Toolmakers, Not the Cure
For nearly four decades, Ampersand Capital Partners has skipped the lottery of drug discovery and quietly backed the companies that make the drug discovery possible. In May 2026 it closed a $1.5 billion fund in a single day.
The $16.3 Billion Company Quietly Running Modern Medicine’s Back Office
IQVIA sits in the machinery between a molecule and a medicine cabinet - running trials, organizing health data and helping drugmakers decide what happens next. Now it is turning that unusually broad view of healthcare into an agentic AI platform.
PARx Solutions
PARx Solutions is a Burlington, Massachusetts healthcare technology and services company that untangles one of medicine's most frustrating chores: prior authorization. Its Prior Authorization Support System (PASS) pairs a secure web portal with a call center of healthcare and reimbursement specialists who handle the paperwork and back-and-forth with health plans on a prescriber's behalf. Because the service is sponsored by drug manufacturers, it is free to physician offices and pharmacies, and it helps patients actually get the medications their doctors prescribed rather than abandoning treatment in the administrative maze.